| Project/Area Number |
02670171
|
|---|
| Research Category |
Grant-in-Aid for General Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
寄生虫学(含医用動物学）
|
|---|
| Research Institution | Kyoto Prefectural University of Medicine |
|---|
Principal Investigator |
YAMADA Minoru Kyoto Prefectural University of Medicine, Department of Medical Zoology, Lecturer, 医学部, 講師 (70106392)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
MATSUDA Shinji Kyoto Prefectural University of Medicine, Department of Medical Zoology, Instruc, 医学部, 助手 (70199800)
YOSHITSUGU Matsumoto Kyo of Medicine, Department of Medical Zoology, Instructor, 医学部, 助手 (00173922)
|
|---|
| Project Period (FY) |
1990 – 1991
|
| Project Status |
Completed (Fiscal Year 1991)
|
| Budget Amount *help |
¥2,300,000 (Direct Cost: ¥2,300,000)
Fiscal Year 1991: ¥600,000 (Direct Cost: ¥600,000)
Fiscal Year 1990: ¥1,700,000 (Direct Cost: ¥1,700,000)
|
|---|
| Keywords | Pneumocystis carinii / pellicle / beta-1, 3-glucan biosynthesis inhibitor / Therapy / Prophylaxis / Aculeacin A / Glucan / Aculeacin A and trimethoprim-sulfamethoxazole / Zymolyase |
|---|
| Research Abstract |
In vivo activities of a beta-1, 3-glucan biosynthesis inhibitor, aculeacin A, against P. carinii and P. carinii pneumonia were investigated using the rat model. Intraperitoneal administration of aculeacin A at 25 mg/kg or 10 mg/kg, or even at 2 mg/kg per day for 2 weeks from 5 Weeks of steroid treatment, affected cyst wall formation, inhibited cyst maturation, and prevented severe pneumonia in steroid-treated rats. Administration of aculeacin A at 10 mg/kg, or even at 2 mg/kg per day earlier, during the initial phase of infection, was more effective suggesting that this drug can be used prophilactically. Simultaneous administration of aculeacin A (0.4 mg/kg) and trimethoprim-sulfamethoxazole (1mg/kg as a dose of sulfamethoxazole) from 5 weeks of steroid treatment showed therapeutic effects against rat pneumocystosis. This data suggested that dosages of both drugs were reduced, though distinct synergy of use of both drugs was not given in this case.
Thus it is hoped that studies of beta-1, 3-glucan biosynthetic inhibitors will not only help in the understanding of the biochemical pathways of the organisms, but also lead to improved human pneumocystosis chemotherapy.
|
